Whose mu fared better? The effect of extended-release naltrexone (XR-NTX) on treatment outcomes for opioid and alcohol users

Quantitative data were collected on total doses received and treatment characteristics
for patients who received XR-NTX as well as evaluation data such as urges to drink
alcohol or use opioids, reported side effects, and substance use (n = 451). Data were
collected at baseline, once a week for the first 3 weeks after the initial dose, and
once a month thereafter, as long as the patient took the medication. In addition,
data were collected for a subset of 114 individuals at 30 and 60 days after the final
dose administration.